- Report
- March 2024
- 192 Pages
Global
From €3251EUR$3,374USD£2,797GBP
€3612EUR$3,749USD£3,107GBP
- Report
- January 2024
- 142 Pages
Global
From €3757EUR$3,899USD£3,232GBP
- Report
- October 2023
- 182 Pages
Global
From €4722EUR$4,900USD£4,061GBP
- Report
- January 2024
- 161 Pages
Global
From €2409EUR$2,500USD£2,072GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €1445EUR$1,500USD£1,243GBP
- Report
- February 2024
- 175 Pages
Global
From €4818EUR$5,000USD£4,144GBP
- Report
- March 2024
- 200 Pages
Global
From €3999EUR$4,150USD£3,440GBP
- Report
- January 2022
- 60 Pages
Global
From €3806EUR$3,950USD£3,274GBP
- Report
- April 2023
- 115 Pages
Global
From €4577EUR$4,750USD£3,937GBP
- Report
- January 2022
- 200 Pages
Global
From €7227EUR$7,500USD£6,217GBP
- Drug Pipelines
- January 2019
- 40 Pages
Global
From €1445EUR$1,500USD£1,243GBP
- Report
- August 2022
United States
From €1869EUR$1,940USD£1,608GBP
- Report
- August 2022
Global
From €761EUR$790USD£655GBP
- Report
- August 2021
Europe
From €3295EUR$3,420USD£2,835GBP
- Report
- August 2021
Global
From €3845EUR$3,990USD£3,307GBP
- Report
- February 2021
Global
From €2852EUR$2,960USD£2,453GBP
- Report
- June 2021
- 56 Pages
Global
From €6740EUR$6,995USD£5,798GBP
- Report
- November 2018
- 86 Pages
Global
From €10595EUR$10,995USD£9,113GBP
- Report
- November 2018
- 40 Pages
Global
From €3850EUR$3,995USD£3,311GBP
- Report
- July 2022
- 100 Pages
Global
From €4620EUR$4,795USD£3,974GBP
Pompe Disease is a rare, inherited disorder caused by a deficiency of the enzyme alpha-glucosidase. This deficiency leads to the accumulation of glycogen in the lysosomes of cells, resulting in progressive muscle weakness and respiratory failure. Endocrine and Metabolic Disorders Drugs are used to treat Pompe Disease. These drugs are designed to replace the missing enzyme, allowing the body to break down the accumulated glycogen and restore normal muscle function.
The Pompe Disease Drug market is a rapidly growing segment of the Endocrine and Metabolic Disorders Drugs market. The increasing prevalence of Pompe Disease and the availability of effective treatments have driven the growth of this market. Companies in this market are focused on developing treatments that are safe and effective, as well as improving existing treatments.
Some companies in the Pompe Disease Drug market include Sanofi, Pfizer, Amicus Therapeutics, and Ultragenyx Pharmaceuticals. Show Less Read more